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Excessive bleeding after cardiac surgery has been attrib-uted to perturbations of the hemostatic system as aresult of surgical trauma and the use of cardiopulmo-nary bypass (CPB). Factor concentrates, such as recom-
binant activated factor VII (rFVIIa) and activated prothrombin
complex concentrates (APCCs, Factor Eight Inhibitor Bypass In-
hibitor [FEIBA]; Baxter Healthcare Corporation, Deerfield, Ill)
have been used with variable success and complications. We
describe a case in which a patient supported by extracorporeal
membrane oxygenation (ECMO) received two doses of rFVIIa
without apparent complication. He then received APCC and sub-
sequently died of massive thrombosis. We discuss the use of factor
concentrates in the surgical setting and make recommendations.
Clinical Summary
A 56-year-old man underwent retransplantation on November 19,
2000, for bronchiolitis obliterans syndrome that developed after
bilateral lung transplantation in 1993 for chronic obstructive pul-
monary disease. The patient had normal hepatic and renal function
and a normal coagulation profile before surgery. After an unevent-
ful anesthetic induction, CPB was required to maintain acceptable
oxygenation during the intraoperative period. There was profuse
blood loss during the procedure, which necessitated transfusion of
large amounts of blood products (Figure 1). Continued blood loss
was observed at the end of the operation, despite discontinuation
and reversal of heparin. Attempts to terminate CPB were unsuc-
cessful, and ECMO was instituted without heparin. The patient
was transported to the intensive care unit with ECMO support. In
the intensive care unit, drainage from the chest tubes exceeded 1
L/h for 2 hours, with no response to continued transfusion of blood
components. Therefore, 7.8 mg (90 g/kg) of rFVIIa (NovoSeven;
NovoNordisk, Copenhagen, Denmark) was administered, with
subsequent decrease in chest tube output (Figure 1). Continued
bleeding necessitated returning the patient to the operating room
for exploration. In the operating room, the cannulation site was
rechecked and judged to be secure, and no discrete bleeding site
was identified. A 4.8-mg dose of rFVIIa was given (exact time was
not noted in the records). After the operation, the bleeding per-
sisted and the patient required additional blood products. Chest
tube drainage had decreased to approximately 300 mL/h of san-
guineous fluid since the administration of the second dose of
rFVIIa. About 6 hours after the last dose of rFVIIa, chest tube
drainage had reached a plateau of 300 mL/h, the patient required
more blood products, and it was decided that additional hemostasis
was required. At this time, because rFVIIa was not available,
APCC was given (the amount was not recorded). At 1:58 am,
several minutes into the infusion of APCC, the patient became
hypotensive and bradycardic, and flow through the ECMO circuit
decreased to 0.5 L/min. Despite bedside thoracotomy and open
cardiac massage, the patient died within 20 minutes. During re-
suscitation, minimal myocardial contraction was apparent, the
heart felt full and immobile, and clots were noted in the ECMO
tubing. The patient’s family declined autopsy.
Discussion
Because there was no autopsy, a definitive cause of death cannot
be determined. However, the final event appeared to be massive
intracardiac and ECMO circuit thrombosis. The thrombotic com-
plications of APCC have limited the use of APCC for the treatment
of bleeding.1 Notably, the package insert for FEIBA states that its
use is contraindicated in the presence of disseminated intravascular
coagulation. In this case, the administration of APCC seemed to
precipitate massive thrombosis. This occurred at least 6 hours after
the last dose of rFVIIa had been administered. Because the half-life
of rFVIIa is 2.3 to 3.0 hours in the bleeding state (as reviewed by
Ingerslev and coworkers2), we conclude that APCC, rather than
rFVIIa, was the main contributing factor to the death of this patient.
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In contrast to the thrombotic effect of APCC, the effect of
rFVIIa on our patient was a reduced chest tube output without
apparent thrombotic event. Various reports have documented the
success of using rFVIIa for a variety of nonapproved situations,
including traumatic bleeding, postoperative lower gastrointestinal
bleeding, warfarin reversal, liver disease, and platelet dysfunction
(as reviewed by Hedner and Erhardtsen3). Thrombotic complica-
tions of rFVIIa have been described in patients with preexisting
risk factors, such as cardiac disease, advanced age, and anomalous
vasculature. We document in this case a beneficial effect of rFVIIa
despite the presence of thrombotic risk factors (postoperative set-
ting of ECMO without heparin). The greater thrombotic potential
of APCC versus rFVIIa is supported mechanistically by an in vitro
assay, which showed that APCC could generate more free throm-
bin than could rFVIIa.4 It should be emphasized that the mecha-
nism of action of rFVIIa in vivo is thought to be regulated,
localized thrombin generation on activated platelet membranes.3
The ability of APCC to generate thrombin in vitro in the absence
of platelet membranes suggests that its prothrombotic tendencies
may be due to dysregulated thrombin production in vivo.
Excessive bleeding after cardiac surgery has been attributed to
a disseminated intravascular coagulation–like phenomenon that
involves uncontrolled activation of both the hemostatic and fi-
brinolytic systems.5 The hemostatic system is activated by inter-
actions of blood components with CPB surfaces as well as by
initiation of the extrinsic clotting pathway by surgical trauma. The
fibrinolytic system is activated by release of tissue plasminogen
activator, which can be promoted by CPB-mediated contact acti-
vation of factor XII and thrombin, hypothermia, and traumatized
endothelial cells. Moreover, returned blood from the pericardial
suction has been shown to contain both tissue factor and tissue
plasminogen activator, potentially leading to activation of both
hemostasis and fibrinolysis. Numerous strategies have been pro-
posed to attenuate the hemostatic disturbances associated with
CPB. Notably, in a recent prospective randomized trial of patients
undergoing procedures that necessitated CPB, those who received
35% more heparin had lessened use of non–red cell blood products
and better preservation of consumable coagulation factors (as
reviewed by Despotis and associates5). It is thought that the use of
heparin in this setting stabilized the hemostatic system, thereby
leading to decreased bleeding.
In conclusion, administration of two doses of rFVIIa resulted in
reduced chest tube output without evidence of thrombosis. Subse-
quent administration of APCC resulted in fatal thrombosis. On the
basis of our observations and a review of the literature, we con-
clude that the thrombotic potential of rFVIIa is much lower than
that of APCC, and therefore its use should be preferred to that of
APCC, particularly for patients who have prothrombotic risk fac-
tors. In addition, we suggest initiation of anticoagulation before
administration of factor concentrates in patients who have an
ongoing stimulus for hemostatic system activation and thrombosis
(eg, ECMO). This last recommendation is made with the intent of
preventing catastrophic thrombosis at the expense of continued
bleeding. On the basis of our experience with this patient and
others at this institution, we recommend that factor concentrates be
given only if the following criteria are met: (1) life-threatening
bleeding is greater than 500 to 1000 mL/h, (2) there is an uniden-
tified source of bleeding other than a surgical source, and (3)
bleeding is unresponsive to pharmacologic agents (eg, L-deamino-
8-D-arginine vasopressin, aprotinin, or aminocaproic acid) and
aggressive transfusion support with several rounds of hemostatic
components (2-3 units of single-donor platelets, 4-6 units of fresh-
frozen plasma, and 10-20 units of cryoprecipitate). These criteria
have been instituted at our facility and are generally met before the
release of factor concentrates.
Figure 1. Blood product use, chest tube output, and coagulation test values plotted against time. Shaded areas
represent time spent in operating room. Patient died at 2 am after FEIBA administration. PT, Prothrombin time; PTT,
partial thromboplastin time; PRBC, packed red blood cells; plts, platelets; FFP, fresh-frozen plasma; cryo,
cryoprecipitate; CTOR, cardiothoracic operating room; ICU, intensive care unit.
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